IBC POLSKA F & P spólka akcyjna (WSE:IBC)

Sage Therapeutics Income Statement

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	9.72	10.83	10.77	6.74	5.75
Revenue Growth (YoY)	-10.29%	0.55%	59.80%	17.20%	-39.76%
Cost of Revenue	6.33	6.79	6.21	3.48	6.95
Gross Profit	3.39	4.04	4.56	3.26	-1.2
Selling, General & Admin	3.5	3.65	3.82	3.6	-
Other Operating Expenses	0.19	0.29	-0.11	-0.45	-0.27
Operating Expenses	3.89	4.09	3.81	3.26	-0.27
Operating Income	-0.5	-0.05	0.75	-0	-0.93
Interest Expense	-0	-0	-0.02	-0.02	-0.02
Interest & Investment Income	0	0	0.02	0.01	0
Other Non Operating Income (Expenses)	-0.01	0.01	-0.02	0	-
EBT Excluding Unusual Items	-0.51	-0.04	0.73	-0.01	-0.94
Gain (Loss) on Sale of Assets	0.02	0.02	-	0	-
Asset Writedown	-0.08	-0.12	-0.14	-0.1	-
Pretax Income	-0.57	-0.15	0.59	-0.1	-0.94
Income Tax Expense	0.01	0.03	0.08	0.02	-0.04
Earnings From Continuing Operations	-0.58	-0.18	0.51	-0.12	-0.9
Minority Interest in Earnings	0.01	0.01	0.01	0.01	-
Net Income	-0.57	-0.17	0.52	-0.11	-0.9
Net Income to Common	-0.57	-0.17	0.52	-0.11	-0.9
Shares Outstanding (Basic)	3	3	3	3	3
Shares Outstanding (Diluted)	3	3	3	3	3
EPS (Basic)	-0.19	-0.06	0.17	-0.04	-0.30
EPS (Diluted)	-0.19	-0.06	0.17	-0.04	-0.30
Free Cash Flow	-0.05	-0.21	0.4	-0.6	-0.06
Free Cash Flow Per Share	-0.02	-0.07	0.13	-0.20	-0.02
Gross Margin	34.86%	37.32%	42.34%	48.37%	-20.90%
Operating Margin	-5.16%	-0.48%	6.94%	-0.02%	-16.16%
Profit Margin	-5.88%	-1.57%	4.82%	-1.58%	-15.67%
Free Cash Flow Margin	-0.55%	-1.97%	3.75%	-8.84%	-1.08%
EBITDA	-0.31	0.1	0.85	0.11	-0.81
EBITDA Margin	-3.18%	0.91%	7.91%	1.66%	-14.06%
D&A For EBITDA	0.19	0.15	0.1	0.11	0.12
EBIT	-0.5	-0.05	0.75	-0	-0.93
EBIT Margin	-5.16%	-0.48%	6.94%	-0.02%	-16.16%
Effective Tax Rate	-	-	13.14%	-	-
Revenue as Reported	9.72	10.83	10.77	674.05	-

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.